TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Testing Pharmacological Therapies for Pregnant Smokers
Brief Summary: Nicotine dependence has not been sufficiently addressed in current state-of-the-science cessation interventions for pregnant smokers. The weight of the evidence from the general population of smokers suggests that nicotine replacement therapies may be beneficial cessation aids for pregnant smokers who are unable to stop smoking. The tremendous potential of these therapies for promoting smoking cessation among pregnant women creates a pressing need for decision tools and protocols to encourage treatment adherence that is essential for rigorous evaluation of the effectiveness of OTC NRT when provided as part of prenatal care. The results of this research could be directly translated to the improvement of obstetrical care providers' clinical practices. Medically supervised use of OTC NRT by pregnant smokers is an alternative to continued smoking that has the potential to substantially increase rates of smoking cessation during pregnancy.


Options:
A: Arm Label: Nicotrol Inhaler; Type: EXPERIMENTAL; Interventions: Drug: Nicotrol Inhaler | Arm Label: Placebo Inhaler; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Inhaler | Intervention Type: DRUG; Name: Nicotrol Inhaler; Assigned to Arm(s): Nicotrol Inhaler | Intervention Type: DRUG; Name: Placebo Inhaler; Assigned to Arm(s): Placebo Inhaler
B: Arm Label: 1 - CBT Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational interviewing for smoking cessation, Behavioral: Cognitive behaviors therapy | Arm Label: 2 - Counseling + NRT; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational interviewing for smoking cessation, Drug: CBT + NRT | Intervention Type: BEHAVIORAL; Name: Motivational interviewing for smoking cessation; Assigned to Arm(s): 1 - CBT Counseling, 2 - Counseling + NRT | Intervention Type: BEHAVIORAL; Name: Cognitive behaviors therapy; Assigned to Arm(s): 1 - CBT Counseling | Intervention Type: DRUG; Name: CBT + NRT; Assigned to Arm(s): 2 - Counseling + NRT
C: Intervention Type: BEHAVIORAL; Name: Nicotine Replacement Therapy; Assigned to Arm(s): N/A
D: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: 2 mg nicotine polacrilex | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: 2 mg nicotine polacrilex; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Testing Pharmacological Therapies for Pregnant Smokers
Brief Summary: Nicotine dependence has not been sufficiently addressed in current state-of-the-science cessation interventions for pregnant smokers. The weight of the evidence from the general population of smokers suggests that nicotine replacement therapies may be beneficial cessation aids for pregnant smokers who are unable to stop smoking. The tremendous potential of these therapies for promoting smoking cessation among pregnant women creates a pressing need for decision tools and protocols to encourage treatment adherence that is essential for rigorous evaluation of the effectiveness of OTC NRT when provided as part of prenatal care. The results of this research could be directly translated to the improvement of obstetrical care providers' clinical practices. Medically supervised use of OTC NRT by pregnant smokers is an alternative to continued smoking that has the potential to substantially increase rates of smoking cessation during pregnancy.


Options:
A: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicotine | Arm Label: Arm B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo nicotine patch | Intervention Type: DRUG; Name: Transdermal Nicotine; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Placebo nicotine patch; Assigned to Arm(s): Arm B
B: Arm Label: 1 - CBT Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational interviewing for smoking cessation, Behavioral: Cognitive behaviors therapy | Arm Label: 2 - Counseling + NRT; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational interviewing for smoking cessation, Drug: CBT + NRT | Intervention Type: BEHAVIORAL; Name: Motivational interviewing for smoking cessation; Assigned to Arm(s): 1 - CBT Counseling, 2 - Counseling + NRT | Intervention Type: BEHAVIORAL; Name: Cognitive behaviors therapy; Assigned to Arm(s): 1 - CBT Counseling | Intervention Type: DRUG; Name: CBT + NRT; Assigned to Arm(s): 2 - Counseling + NRT
C: Arm Label: 8 weeks transdermal nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal nicotine patch | Arm Label: 24 weeks transdermal nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal nicotine patch | Arm Label: 52 weeks transdermal nicotine; Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine patch | Intervention Type: DRUG; Name: Transdermal nicotine patch; Assigned to Arm(s): 24 weeks transdermal nicotine, 52 weeks transdermal nicotine, 8 weeks transdermal nicotine
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Dose adjustment of nicotine replacement therapies | Arm Label: 2; Type: OTHER; Interventions: Drug: nicotine patch | Intervention Type: PROCEDURE; Name: Dose adjustment of nicotine replacement therapies; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Testing Pharmacological Therapies for Pregnant Smokers
Brief Summary: Nicotine dependence has not been sufficiently addressed in current state-of-the-science cessation interventions for pregnant smokers. The weight of the evidence from the general population of smokers suggests that nicotine replacement therapies may be beneficial cessation aids for pregnant smokers who are unable to stop smoking. The tremendous potential of these therapies for promoting smoking cessation among pregnant women creates a pressing need for decision tools and protocols to encourage treatment adherence that is essential for rigorous evaluation of the effectiveness of OTC NRT when provided as part of prenatal care. The results of this research could be directly translated to the improvement of obstetrical care providers' clinical practices. Medically supervised use of OTC NRT by pregnant smokers is an alternative to continued smoking that has the potential to substantially increase rates of smoking cessation during pregnancy.


Options:
A: Intervention Type: BEHAVIORAL; Name: Smoking cessation counseling delivered by telephone; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): N/A
C: Arm Label: 1 - CBT Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational interviewing for smoking cessation, Behavioral: Cognitive behaviors therapy | Arm Label: 2 - Counseling + NRT; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational interviewing for smoking cessation, Drug: CBT + NRT | Intervention Type: BEHAVIORAL; Name: Motivational interviewing for smoking cessation; Assigned to Arm(s): 1 - CBT Counseling, 2 - Counseling + NRT | Intervention Type: BEHAVIORAL; Name: Cognitive behaviors therapy; Assigned to Arm(s): 1 - CBT Counseling | Intervention Type: DRUG; Name: CBT + NRT; Assigned to Arm(s): 2 - Counseling + NRT
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Computerized brief intervention (5As); Type: EXPERIMENTAL; Interventions: Behavioral: Computer-delivered brief intervention (5As) | Arm Label: Contingency Management Alone; Type: EXPERIMENTAL; Interventions: Behavioral: Contingency Management | Arm Label: Combined Brief Intervention and CM; Type: EXPERIMENTAL; Interventions: Behavioral: Computer-delivered brief intervention (5As), Behavioral: Contingency Management | Intervention Type: BEHAVIORAL; Name: Computer-delivered brief intervention (5As); Assigned to Arm(s): Combined Brief Intervention and CM, Computerized brief intervention (5As) | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): Combined Brief Intervention and CM, Contingency Management Alone

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Testing Pharmacological Therapies for Pregnant Smokers
Brief Summary: Nicotine dependence has not been sufficiently addressed in current state-of-the-science cessation interventions for pregnant smokers. The weight of the evidence from the general population of smokers suggests that nicotine replacement therapies may be beneficial cessation aids for pregnant smokers who are unable to stop smoking. The tremendous potential of these therapies for promoting smoking cessation among pregnant women creates a pressing need for decision tools and protocols to encourage treatment adherence that is essential for rigorous evaluation of the effectiveness of OTC NRT when provided as part of prenatal care. The results of this research could be directly translated to the improvement of obstetrical care providers' clinical practices. Medically supervised use of OTC NRT by pregnant smokers is an alternative to continued smoking that has the potential to substantially increase rates of smoking cessation during pregnancy.


Options:
A: Arm Label: PROOF cohort; Type: N/A; Interventions: N/A
B: Arm Label: Bupropion and Weight Concerns intervention; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: weight concerns intervention | Arm Label: Placebo and Weight Concerns; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Behavioral: weight concerns intervention | Arm Label: Bupropion and standard smoking cessation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: smoking cessation intervention | Arm Label: Placebo and standard smoking cessation; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: smoking cessation intervention | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion and Weight Concerns intervention, Bupropion and standard smoking cessation | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo and Weight Concerns, Placebo and standard smoking cessation | Intervention Type: BEHAVIORAL; Name: weight concerns intervention; Assigned to Arm(s): Bupropion and Weight Concerns intervention, Placebo and Weight Concerns | Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): Bupropion and standard smoking cessation, Placebo and standard smoking cessation
C: Arm Label: 1 - CBT Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational interviewing for smoking cessation, Behavioral: Cognitive behaviors therapy | Arm Label: 2 - Counseling + NRT; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational interviewing for smoking cessation, Drug: CBT + NRT | Intervention Type: BEHAVIORAL; Name: Motivational interviewing for smoking cessation; Assigned to Arm(s): 1 - CBT Counseling, 2 - Counseling + NRT | Intervention Type: BEHAVIORAL; Name: Cognitive behaviors therapy; Assigned to Arm(s): 1 - CBT Counseling | Intervention Type: DRUG; Name: CBT + NRT; Assigned to Arm(s): 2 - Counseling + NRT
D: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Testing Pharmacological Therapies for Pregnant Smokers
Brief Summary: Nicotine dependence has not been sufficiently addressed in current state-of-the-science cessation interventions for pregnant smokers. The weight of the evidence from the general population of smokers suggests that nicotine replacement therapies may be beneficial cessation aids for pregnant smokers who are unable to stop smoking. The tremendous potential of these therapies for promoting smoking cessation among pregnant women creates a pressing need for decision tools and protocols to encourage treatment adherence that is essential for rigorous evaluation of the effectiveness of OTC NRT when provided as part of prenatal care. The results of this research could be directly translated to the improvement of obstetrical care providers' clinical practices. Medically supervised use of OTC NRT by pregnant smokers is an alternative to continued smoking that has the potential to substantially increase rates of smoking cessation during pregnancy.


Options:
A: Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): N/A
B: Arm Label: 1 - CBT Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational interviewing for smoking cessation, Behavioral: Cognitive behaviors therapy | Arm Label: 2 - Counseling + NRT; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational interviewing for smoking cessation, Drug: CBT + NRT | Intervention Type: BEHAVIORAL; Name: Motivational interviewing for smoking cessation; Assigned to Arm(s): 1 - CBT Counseling, 2 - Counseling + NRT | Intervention Type: BEHAVIORAL; Name: Cognitive behaviors therapy; Assigned to Arm(s): 1 - CBT Counseling | Intervention Type: DRUG; Name: CBT + NRT; Assigned to Arm(s): 2 - Counseling + NRT
C: Arm Label: Implementation of intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Training in smoking cessation counseling | Arm Label: No implementation of the intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Training in smoking cessation counseling; Assigned to Arm(s): Implementation of intervention
D: Arm Label: MiQuit; Type: EXPERIMENTAL; Interventions: Behavioral: MiQuit | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MiQuit; Assigned to Arm(s): MiQuit

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Mulitcentre, Double-blind, Randomised, Fixed-dose Evaluation of the Safety and Efficacy of Lamictal (Lamotrigine) Compared to Placebo as an add-on Therapy to Lithium or Another Mood Stabiliser in the Treatment of Bipolar Depression, Followed by Long-term Prevention of Relapse and Recurrence of Depression and/or Mania in Patients With Bipolar Disorder
Brief Summary: This is a study that, in the first 16 weeks, investigates whether lamotrigine versus placebo offers effect on depressive episodes for patients with bipolar disorder (also known as manic depressive disorder) who use lithium. In the following 50 weeks it is investigated whether these patients experience effect on their depressive and/ or (hypo)manic episodes.


Options:
A: Intervention Type: DRUG; Name: lamotrigine; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Psychoeduction; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive-Behavioral Therapy; Assigned to Arm(s): N/A
C: Arm Label: Lithium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lithium | Arm Label: Divalproex; Type: ACTIVE_COMPARATOR; Interventions: Drug: Divalproex | Arm Label: Lithium plus Quetiapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lithium, Drug: Quetiapine | Arm Label: Lithium plus Lamotrigine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lithium, Drug: Lamotrigine | Arm Label: Divalproex plus Quetiapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Divalproex, Drug: Quetiapine | Arm Label: Divalproex plus Lamotrigine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Divalproex, Drug: Lamotrigine | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): Lithium, Lithium plus Lamotrigine, Lithium plus Quetiapine | Intervention Type: DRUG; Name: Divalproex; Assigned to Arm(s): Divalproex, Divalproex plus Lamotrigine, Divalproex plus Quetiapine | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): Divalproex plus Lamotrigine, Lithium plus Lamotrigine | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Divalproex plus Quetiapine, Lithium plus Quetiapine
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: BW430C(lamotrigine); Type: ACTIVE_COMPARATOR; Interventions: Drug: lamotrigine | Intervention Type: DRUG; Name: lamotrigine; Assigned to Arm(s): BW430C(lamotrigine) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The RATIO Registry: French Registry on Opportunistic and Severe Bacterial Infections and Lymphoma in Patients Treated With TNF-a Antagonists
Brief Summary: The RATIO registry is a French registry designed by a multidisciplinary group to collect data on opportunistic and severe bacterial infections and lymphoma in patients treated with TNF-a antagonists ( infliximab, etanercept and adalimumab). A total of 486 medical units in metropolitan France participate in the RATIO registry. All diagnosis are retained after validation by 2 qualified infectious disease or haematologist physicians (on the basis of the standardized case report form, the hospitalisation summary, and the microbiological and radiological results). Risk factors for developing these conditions when treated by TNF-a antagonists will be identified in a case control study. Incidence of these diseases will be calculated.


Options:
A: Arm Label: Secukinumab; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 300 mg | Arm Label: Placebo then Secukinumab; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: DRUG; Name: Secukinumab 300 mg; Assigned to Arm(s): Secukinumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo then Secukinumab
B: Arm Label: Adalimumab; Type: OTHER; Interventions: Drug: adalimumab | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): Adalimumab
C: Arm Label: Investigational drug - Dose 1; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Investigational drug - Dose 2; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ACT-128800; Assigned to Arm(s): Investigational drug - Dose 1, Investigational drug - Dose 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching placebo
D: Intervention Type: DRUG; Name: TNF-alpha antagonists; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The RATIO Registry: French Registry on Opportunistic and Severe Bacterial Infections and Lymphoma in Patients Treated With TNF-a Antagonists
Brief Summary: The RATIO registry is a French registry designed by a multidisciplinary group to collect data on opportunistic and severe bacterial infections and lymphoma in patients treated with TNF-a antagonists ( infliximab, etanercept and adalimumab). A total of 486 medical units in metropolitan France participate in the RATIO registry. All diagnosis are retained after validation by 2 qualified infectious disease or haematologist physicians (on the basis of the standardized case report form, the hospitalisation summary, and the microbiological and radiological results). Risk factors for developing these conditions when treated by TNF-a antagonists will be identified in a case control study. Incidence of these diseases will be calculated.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: ABT-874 | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Biological: etanercept | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: BIOLOGICAL; Name: ABT-874; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C
B: Intervention Type: DRUG; Name: TNF-alpha antagonists; Assigned to Arm(s): N/A
C: Arm Label: CNTO1275 (ustekinumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Intervention Type: DRUG; Name: CNTO 1275 63 mg; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo
D: Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The RATIO Registry: French Registry on Opportunistic and Severe Bacterial Infections and Lymphoma in Patients Treated With TNF-a Antagonists
Brief Summary: The RATIO registry is a French registry designed by a multidisciplinary group to collect data on opportunistic and severe bacterial infections and lymphoma in patients treated with TNF-a antagonists ( infliximab, etanercept and adalimumab). A total of 486 medical units in metropolitan France participate in the RATIO registry. All diagnosis are retained after validation by 2 qualified infectious disease or haematologist physicians (on the basis of the standardized case report form, the hospitalisation summary, and the microbiological and radiological results). Risk factors for developing these conditions when treated by TNF-a antagonists will be identified in a case control study. Incidence of these diseases will be calculated.


Options:
A: Intervention Type: DRUG; Name: TNF-alpha antagonists; Assigned to Arm(s): N/A
B: Arm Label: Group I: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg | Arm Label: Group II: Ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 45 mg | Arm Label: Group III: Ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 90 mg | Intervention Type: DRUG; Name: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg; Assigned to Arm(s): Group I: Placebo | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 45 mg; Assigned to Arm(s): Group II: Ustekinumab 45 mg | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 90 mg; Assigned to Arm(s): Group III: Ustekinumab 90 mg
C: Arm Label: LAS41008; Type: EXPERIMENTAL; Interventions: Drug: LAS41008 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LASW1835; Type: ACTIVE_COMPARATOR; Interventions: Drug: LASW1835 | Intervention Type: DRUG; Name: LAS41008; Assigned to Arm(s): LAS41008 | Intervention Type: DRUG; Name: LASW1835; Assigned to Arm(s): LASW1835 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: CNTO1275 (ustekinumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Intervention Type: DRUG; Name: CNTO 1275 63 mg; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo

Answer: A